SYROS PHARMACEUTICALS INC (SYRS)
US87184Q2066 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 58.27M | 139.53M | 167.50M | 92.30M | 174.00M | |||
| Marketable Securities | N/A | 0.00 | 34.80M | 38.10M | 0.00 | |||
| Receivables | N/A | 0.00 | 1.70M | 3.00M | 2.30M | |||
| Other Current Assets | 5.66M | 5.45M | 7.40M | 3.20M | 2.20M | |||
| Total Current Assets | 63.93M | 144.98M | 211.40M | 136.60M | 178.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 17.58M | 19.48M | 24.70M | 27.30M | 29.60M | |||
| Investments And Advances | N/A | N/A | 0.00 | 13.00M | N/A | |||
| Other Non-Current Assets | 3.48M | 3.71M | 8.40M | 6.00M | 5.10M | |||
| Total Non-Current Assets | 21.06M | 23.19M | 33.10M | 46.30M | 34.70M | |||
| TOTAL ASSETS | 85.00M | 168.17M | 244.50M | 182.90M | 213.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 6.67M | 100.00K | 300.00K | 300.00K | |||
| Accrued Expenses | 18.75M | 18.47M | 20.00M | 17.30M | 12.50M | |||
| Accounts Payable | 9.65M | 11.54M | 6.40M | 3.70M | 3.60M | |||
| Other Current Liabilities | N/A | 0.00 | 4.30M | 10.20M | 12.20M | |||
| Total Current Liabilities | 28.39M | 36.68M | 30.80M | 31.50M | 28.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 41.08M | 34.56M | 40.60M | 40.30M | 39.90M | |||
| Other Non-Current Liabilities | 26.64M | 80.28M | 45.30M | 25.90M | 54.20M | |||
| Total Non-Current Liabilities | 67.73M | 114.83M | 86.00M | 66.20M | 94.10M | |||
| TOTAL LIABILITIES | 96.12M | 151.51M | 116.80M | 97.70M | 122.70M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -756.24M | -722.81M | -558.20M | -463.60M | -377.00M | |||
| Additional Paid In Capital | 745.09M | 739.44M | 685.80M | 548.80M | 467.50M | |||
| Common Shares | 27.00K | 26.00K | 0.00 | 100.00K | 100.00K | |||
| Other Shareholders' Equity | N/A | 0.00 | 100.00K | -100.00K | N/A | |||
| Shares Outstanding | 26.83M | 26.45M | 20.30M | 6.20M | 5.60M | |||
| Tangible Book Value per Share | -0.41 | 0.63 | 6.29 | 13.74 | 16.18 | |||
| Total Shareholders' Equity | -11.12M | 16.66M | 127.70M | 85.20M | 90.60M | |||
| TOTAL LIABILITIES AND EQUITY | 85.00M | 168.17M | 244.50M | 182.90M | 213.30M | |||
| Statistics | ||||||||
| Debt/Equity | -3.69 | 2.07 | 0.32 | 0.47 | 0.44 | |||
| Current Ratio | 2.25 | 3.95 | 6.86 | 4.34 | 6.24 | |||
| Return On Assets (ROA) | -115.08% | -97.86% | -38.71% | -47.33% | -39.40% | |||
| Return On Equity (ROE) | N/A | -987.72% | -74.12% | -101.60% | -92.76% | |||
All data in USD , ROIC based on taxRate of 0.21